Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia

Inclusion Criteria: * Age: 18-65 years * Patients with Cluster of Differentiation 19 (CD19) positive B cell malignancies as confirmed by flow cytometry * Refractory or relapsed B cell-acute lymphoblastic leukemia * No available curative treatment options (such as hematopoietic stem cell transplantation) * Stage III-IV disease * Creatinine \< 2.5 mg/dl * Aspartate transaminase-alanine transaminase ratio \< 3x normal * Bilirubin \< 2.0 mg/dl * Karnofsky performance status \>= 60 * Expected survival time \> 3 months * Adequate venous access for apheresis * Ability to understand and provide informed consent Exclusion Criteria: * Pregnant or lactating women * Patients requiring T cell immunosuppressive therapy * Active central nervous system leukemia * Any concurrent active malignancies * Patients with a history of a seizure disorder or cardiac disorder * Patients with human immunodeficiency virus, hepatitis B or C infection * Uncontrolled active infection